Rhabdoid TumorSymptoms, Doctors, Treatments, Advances & More
Learn About Rhabdoid Tumor
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Orthopaedics Clinic At Lauritzen Outpatient Center
Sean Mcgarry is an Orthopedics provider practicing medicine in Omaha, Nebraska. He has been practicing medicine for over 28 years. Dr. Mcgarry is rated as a Distinguished provider by MediFind in the treatment of Rhabdoid Tumor. He is also highly rated in 21 other conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Bone Tumor, Osteosarcoma, Myxoid Liposarcoma, and Hip Replacement.
Advocate Lutheran General Cancer Institute
Pamela Kaiser is a Hematologist and an Oncologist practicing medicine in Park Ridge, Illinois. Dr. Kaiser is rated as an Advanced provider by MediFind in the treatment of Rhabdoid Tumor. She is also highly rated in 21 other conditions, according to our data. Her clinical expertise encompasses Angiosarcoma, Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, and Endoscopy. Dr. Kaiser is board certified in American Board Of Internal Medicine, Medical Oncology.
Aurora Orthopedics
Nicholas Webber is an Orthopedics provider practicing medicine in Milwaukee, Wisconsin. Dr. Webber is rated as an Advanced provider by MediFind in the treatment of Rhabdoid Tumor. He is also highly rated in 30 other conditions, according to our data. His clinical expertise encompasses Osteoarthritis, Osteonecrosis, Rhabdomyosarcoma Embryonal, Hip Replacement, and Knee Replacement. Dr. Webber is board certified in American Board Of Orthopaedic Surgery.
Summary: 3CAR is being done to investigate an immunotherapy for patients with solid tumors. It is a Phase I clinical trial evaluating the use of autologous T cells genetically engineered to express B7-H3-CARs for patients ≤ 21 years old, with relapsed/refractory B7-H3+ solid tumors. This study will evaluate the safety and maximum tolerated dose of B7-H3-CAR T cells.The purpose of this study is to find the ...
Summary: The phase I portion of this study is designed for children or adolescents and young adults (AYA) with a diagnosis of a solid tumor that has recurred (come back after treatment) or is refractory (never completely went away). The trial will test 2 combinations of therapy and participants will be randomly assigned to either Arm A or Arm B. The purpose of the phase I study is to determine the highest ...